We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Endometrium Undergoes Gene Expression Shifts During Menstrual Cycle

By LabMedica International staff writers
Posted on 29 Sep 2020
In a human menstrual cycle the endometrium undergoes remodeling, shedding and regeneration, all of which are driven by substantial gene expression changes in the underlying cellular hierarchy. More...


Despite its importance in human fertility and regenerative biology, our understanding of this unique type of tissue homeostasis remains rudimentary A new single-cell transcriptomic study has shown that the window during which human embryos can implant into the endometrium opens with an abrupt change in gene expression of endometrial cells.

A team of bioengineers at Stanford University (Stanford, CA, USA) and their colleagues obtained endometrial biopsies from 19 healthy individuals between four and 27 days after the start of their last menstrual period. They captured single cells for RNA-seq analysis using Fluidigm C1 medium chips (South San Francisco, CA, USA) and, to validate their findings, processed additional samples from 10 other healthy individuals using the 10x Chromium system (10x Genomics, Pleasanton, CA, USA).

The scientists reported that an analysis of the genes and markers expressed by the endometrial cells pointed to the presence of six cell types, four of which, stromal fibroblasts, endothelium, macrophages, and lymphocytes, could readily be identified. The two other cell types both expressed epithelium-linked markers as well as other genes, leading the investigators to characterize one cell type as 'ciliated epithelium' and the other as 'unciliated epithelium.'

The team also examined the transcriptomes of endometrial cells over time to uncover four major phases of endometrial transformation. For instance, the global transcriptome of unciliated epithelial cells was fairly consistent from phase one through phase three, but it changed abruptly with the start of phase four. At that time, those cells began to express genes like PAEP, GPX3, and CXCL14, whose expression has previously been linked to the window of implantation (WOI).

At the same time, stromal fibroblasts upregulated genes like DKK1 and CRYAB during phase four, as well as the decidualization-initiating transcription factor FOXO1 and the decidualization stromal marker IL5. The change in gene expression among stromal fibroblasts upon entering the WOI was not quite as abrupt as it was among the epithelial cells. The WOI closes gradually and one group of genes, marked by PAEP and GPX3, are expressed throughout phase four and into phase one of the next cycle, while another group of genes that include CXC14, MAOA, and DPP4 decline in expression toward the end of phase four.

The authors concluded that their study provided a high-resolution molecular and cellular characterization of human endometrial transformation across the menstrual cycle, providing insights into this essential physiological process. The study was published on September 14, 2020 in the journal Nature Medicine.

Related Links:
Stanford University
Fluidigm
10x Genomics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gastrointestinal Panel
Xpert® GI Panel
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.